Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 July 2026, providing investors with the latest insights into its performance and prospects.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 Jul 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 18 June 2026, providing investors with the latest insights into its performance and outlook.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 04 June 2026, providing investors with the latest insights into its performance and prospects.

Vista Pharmaceuticals Ltd. reported a catastrophic fourth quarter for FY2026, with net sales collapsing to absolute zero from ₹3.23 crores in the same quarter last year, marking a complete operational shutdown. The micro-cap pharmaceutical company posted a net loss of ₹5.86 crores in Q4 FY26, representing a dramatic deterioration from the ₹1.50 crore loss recorded in Q4 FY25. The stock, however, surged 7.37% on May 29, 2026, to close at ₹8.59, reflecting speculative trading rather than fundamental improvement in a company with a market capitalisation of just ₹49.00 crores.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 20 May 2026, providing investors with the latest insights into its performance and prospects.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 Jul 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 26 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 03 April 2026, providing investors with the latest insights into its performance and prospects.

Vista Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Vista Pharmaceuticals Ltd’s stock touched a fresh 52-week low of Rs.6.05 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical formulation company, reported deeply troubling Q3 FY26 results that underscore the severe operational and financial distress gripping the organisation. The company posted a net loss of ₹2.32 crores for the quarter ended December 2025, representing a 75.76% deterioration from the ₹1.32 crores loss recorded in Q3 FY25. With a market capitalisation of just ₹45.00 crores, the stock plunged 5.91% following the results announcement, closing at ₹6.85 on February 13, 2026—a mere 4.26% above its 52-week low of ₹6.57.